EUVIMEDScopri EUVIMED
Crossref

NMI promotes tumor progression and gemcitabine resistance in pancreatic cancer via STAT3‐IFIT3 axis

Haifeng Hu, Borui Li, Haidi Chen, Guixiogn Fan, Zeng Ye, Shunrong Ji, Xianjun Yu, Xiaowu Xu, Yi Qin

Molecular Carcinogenesis · 2024

DOI: 10.1002/mc.23645 ↗

At a glance

Journal article in Molecular Carcinogenesis, 2024. Written by Haifeng Hu and 8 co-authors. Institution: Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China. Major MEDLINE topics: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms. Cited 5 times so far (Crossref); 24 references. Funded by: National Natural Science Foundation of China, Shanghai Municipal Science and Technology Major Project, Scientific Innovation Project of Shanghai Education Committee.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

N‐myc and STAT interactor (NMI) has been reported to interact with several transcription factors, including STATs family, c‐Myc, N‐Myc, and BRCA1, to indirectly affect transcription events and participate in multiple cellular processes. However, its function in pancreatic ductal adenocarcinoma (PDAC) has seldom been studied. In this study, we investigated the regulation of NMI on PDAC progression and uncovered the underlying molecular mechanisms. We found that NMI expression was significantly upregulated in PDAC and high NMI expression was related to a worse patient survival. Cell proliferation and migration assay, including cell viability, transwell assay, wound healing, and subcutaneous mouse model were utilized to confirm the function of NMI in PDAC progression. Downregulation of NMI abrogates tumor progression of PDAC both in vitro and in vivo. RNA sequencing was utilized to identify the downstream molecules of NMI and interferon‐induced protein with tetratricopeptide repeats 3 (IFIT3) was confirmed to be regulated by NMI in both mRNA and protein level. The binding function of NMI to STAT3 was essential in regulating the IFIT3 expression. Moreover, the NMI/STAT3‐IFIT3 axis was identified to markedly facilitate the gemcitabine resistance in PDAC cells.

Subjects

MeSH terms (MEDLINE)

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsAnimalsHumansMiceCell Line, TumorCell ProliferationGemcitabineGene Expression Regulation, NeoplasticIntracellular Signaling Peptides and ProteinsSTAT3 Transcription Factor

Author keywords

IFIT3NMISTAT3pancreatic ductal adenocarcinoma

Substances

GemcitabineIFIT3 protein, humanIntracellular Signaling Peptides and ProteinsSTAT3 protein, humanSTAT3 Transcription FactorIfit3 protein, mouseStat3 protein, mouseNMI protein, humanNMI protein, mouse

Authors and institutions

  • Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • Shanghai Pancreatic Cancer Institute, Shanghai, China.
  • Pancreatic Cancer Institute, Fudan University, Shanghai, China.

Funding

  • National Natural Science Foundation of China
  • Shanghai Municipal Science and Technology Major Project
  • Scientific Innovation Project of Shanghai Education Committee
  • Clinical Research Plan of Shanghai Hospital Development Center
  • Xuhui District Artificial Intelligence Medical Hospital Cooperation Project
  • Science and Technology Commission of Shanghai Municipality
  • National Science Foundation of China

Cite

APA

Hu, H., Li, B., Chen, H., Fan, G., Ye, Z., Ji, S., Yu, X., Xu, X., & Qin, Y. (2024). NMI promotes tumor progression and gemcitabine resistance in pancreatic cancer via STAT3‐IFIT3 axis. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23645

Vancouver

Hu H, Li B, Chen H, Fan G, Ye Z, Ji S, et al. NMI promotes tumor progression and gemcitabine resistance in pancreatic cancer via STAT3‐IFIT3 axis. Molecular Carcinogenesis. 2024. doi:10.1002/mc.23645

BibTeX
@article{Hu2024,
  author = {Hu, Haifeng and Li, Borui and Chen, Haidi and Fan, Guixiogn and Ye, Zeng and Ji, Shunrong and Yu, Xianjun and Xu, Xiaowu and Qin, Yi},
  title = {NMI promotes tumor progression and gemcitabine resistance in pancreatic cancer via STAT3‐IFIT3 axis},
  journal = {Molecular Carcinogenesis},
  year = {2024},
  doi = {10.1002/mc.23645}
}
Start for free →